In focus · trending topic

novel capsids

2 stories · following the connections

Voyager Therapeutics Highlights Lead Program VY-AADC for Advanced Parkinson’s Disease, AAV Novel Capsid and Delivery Optimization Efforts, and Pipeline Programs at its R&D Day

By Nasdaq OMXNov 16, 2017, 9:45 PM UTC

Voyager Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Highlights

By Nasdaq OMXNov 2, 2017, 8:01 PM UTC